Results 131 to 140 of about 136,889 (307)

Phylogenetic surveillance of viral genetic diversity and the evolving molecular epidemiology of human immunodeficiency virus type 1

, 2007
With ongoing generation of viral genetic diversity and increasing levels of migration, the global human immunodeficiency virus type 1 (HIV-1) epidemic is becoming increasingly heterogeneous.
Vandamme, Anne-Mieke, ?, ?, Kellam, Paul, Pillay, Deenan, Rambaut, Andrew, Gifford, Robert J., de Oliveira, Tulio, Pybus, Oliver G., Dunn, David   +8 more
core   +1 more source

Molecular dynamics simulations elucidate the misfolding mechanisms of secretion‐defective pancreatic lipase variants

The FEBS Journal, EarlyView.
Misfolding mutations in pancreatic lipase have been identified as potential contributors of chronic pancreatitis, an inflammatory disease of the human pancreas. Here, we describe the effect of these misfolding mutations on pancreatic lipase structure using molecular dynamics simulations and structural modeling.
Gyula Hoffka, András Szabó
wiley   +1 more source

A multidisciplinary, AI‐supported quality improvement intervention to manage polypharmacy in aging people with HIV

HIV Medicine, EarlyView.
Abstract Objectives Aging people with HIV are increasingly affected by multimorbidity and polypharmacy, which heighten the risk of drug–drug interactions (DDIs) and potentially inappropriate medications (PIMs). This study evaluated a multidisciplinary, AI‐supported quality improvement intervention designed to optimize polypharmacy management in older ...
Jovana Milic, Antonia Pugliese, Michela Belli, Gian Luca Lonardi, Caterina Ruffilli, Tommaso Albano, Marco Visicaro, Martina Ricciardetto, Pierluigi De Cosmo, Chiara Mussi, Francesca Gandolfi, Cristina Mussini, Costantino Grana, Giovanni Guaraldi   +13 more
wiley   +1 more source

HIV‐1 viral load and reservoir size remain stable following SARS‐CoV‐2 mRNA vaccination in people with HIV

HIV Medicine, EarlyView.
Abstract Background The potent immunogenicity of mRNA vaccination raised concerns about its impact on HIV‐1 viral load (VL) and reservoir size in people with HIV, which could drive vaccine hesitancy. As part of a prospective clinical trial, we investigated whether SARS‐CoV‐2 mRNA vaccination induced changes in VL and reservoir size after a 1‐year three‐
Oscar Kieri, Bianca B Jütte, Jan Vesterbacka, Soo Aleman, Hans‐Gustaf Ljunggren, Marcus Buggert, J Peter Svensson, Anders Sönnerborg, Piotr Nowak   +8 more
wiley   +1 more source

Systematic screening for age‐related comorbidities: Health care optimization among persons with HIV in an outpatient setting

HIV Medicine, EarlyView.
Abstract Background Age‐related comorbidities occur earlier and more frequently in people with HIV (PWH) than in the general population and have emerged as a key challenge in long‐term HIV care. Unfortunately, many of these conditions remain undiagnosed, and systematic screening in clinical practice remains limited.
Anna Katrine Haslund Roed, Anne‐Mette Lebech, Sabine Singh, Ole Kirk, Susanne Dam Nielsen   +4 more
wiley   +1 more source

Characteristics, Immunological Response & Treatment Outcomes of HIV-2 Compared with HIV-1 & Dual Infections (HIV 1/2) in Mumbai

, 2010
Information available on HIV-2 and dual infection (HIV-1/2) is limited. This study was carried out among HIV positive individuals in an urban referral clinic in Khar, Mumbai, India, to report on relative proportions of HIV-1, HIV-2 and HIV-1/2 and ...
Manzi, M, Harries, AD, Rony, Zachariah, Ladomirska, Joanna, Harries, A D, Wilson, N, Bhanumati, Varghese, Alaka, Deshpande, Homa, Mansoor, Chiara, Montaldo   +9 more
core  

Real‐world clinical and laboratory changes after switching to two‐drug regimen in HIV‐suppressed individuals: 48 weeks and beyond

HIV Medicine, EarlyView.
Abstract Introduction Two‐drug regimens (2DRs) may reduce long‐term drug toxicities and drug‐drug interactions for people with HIV (PWH) on antiretroviral therapy (ART). This study evaluated clinical and laboratory outcomes in PWH who switched from standard ART to dolutegravir and lamivudine (DTG + 3TC) in real‐world settings.
Tommy Hing‐cheung Tang, Ruby Tsz‐shan Kwong, Phillip Chan, Kwok‐wai Lam, Helen Shuk‐ying Chan, Man‐yee Chu, Wilson Lam, Tak‐chiu Wu, Wai‐shing Leung, Sai‐kwong Yung, Wan‐man Ting, Annabel Kai‐tung Choy, Joe Lok‐fung Tung, Jason Ka‐wah Fong, Daniel Kai‐yeung Yeung, Man‐po Lee   +15 more
wiley   +1 more source

Combined analysis of Two-Year Follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 nfection: OzCombo 1 and 2

, 2003
Purpose: To compare inhibition of HIV replication, improvements in CD4+ T-cell counts, metabolic parameters, and body shape changes after 2 years of assigned therapy in OzCombo patients.
Cooper, D.A., Todhunter, L., Sowden, D., Hoy, J.N., Papanaoum, K., Quin, J., Genn, W., Amin, J., Mulholland, J., Bryant, M., Shaw, D.V., Ferguson, W., Baker, D., Moore, A., Scull, N., James, R., French, M.A., Street, A., Packham, D., Foreman, E., Doong, N.C., Rawlinsen, M., McCormack, C., Norrito, L., Dwyer, D., Quan, D., Roney, J., Waddell, R., French, M.R., Carr, A., De Graaf, B., Garsia, R., Law, M., Beveridge, A., Kotsiou, G., Fordham, M., Emery, S., Rebic, D., Mallal, S.   +38 more
core  

Temporal shifts in antiretroviral therapy regimens and metabolic outcomes in people living with HIV: A systematic review and meta‐analysis

HIV Medicine, EarlyView.
Abstract Introduction Antiretroviral therapy (ART) for people living with HIV has led to dramatically reduced mortality and improved life expectancy. This achievement is accompanied by a higher risk for metabolic and other non‐communicable diseases. The role and contribution of various ART regimens to adverse metabolic outcomes are not fully understood.
Melani Ratih Mahanani, Myo Chit, Sophie Mohr, Elisenda Cama i Gibernau, Svetlana Hetjens, Volker Winkler, Hans‐Michael Steffen, Florian Neuhann   +7 more
wiley   +1 more source

A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants

, 2010
Variants resistant to compounds specifically targeting HCV are observed in clinical trials. A multi-variant viral dynamic model was developed to quantify the evolution and in vivo fitness of variants in subjects dosed with monotherapy of an HCV protease ...
Stefan Zeuzem, Randle, John C. R., Randle John C. R., Lin, Chao, Kwong Ann D., Bambang S Adiwijaya, John C. R. Randle, Sarrazin, Christoph, Paul R. Caron, Herrmann Eva, Zeuzem Stefan, Christoph Sarrazin, Garg Varun, Kieffer, Tara, Brian Hare, Hare, Brian, Varun Garg, Lin Chao, Kieffer Tara, Herrmann, Eva, Caron, Paul R., Kwong, Ann D., Tara Kieffer, Ann D Kwong, Sarrazin Christoph, Chao Lin, Bambang S. Adiwijaya, Adiwijaya, Bambang S., Hare Brian, Paul R Caron, Caron Paul R., Garg, Varun, Eva Herrmann, Ann D. Kwong, John C R Randle, Adiwijaya Bambang S., Zeuzem, Stefan   +36 more
core   +1 more source